"I love FASENRA® (benralizumab) for Severe Eosinophilic Asthma | For HCPs"

2022-07-13 15:13:44

Toggle navigation For US Healthcare Professionals OnlyAZ Medical InformationPrescribing InformationView Patient WebsiteIndicationEFFICACYDOSINGSUPPORTRESOURCESFor US Healthcare Professionals OnlyAZ Medical InformationPrescribing InformationView Patient WebsiteIndicationEFFICACYDOSINGSUPPORTRESOURCESefficacyMOAsafetydosingsupportresourcesdiagnosisMoreHide efficacy MOA safety dosing support resources diagnosis More Hide Power to Prevent Exacerbations Protection from OCS Study Designs References All Resources Access 360 How to Obtain FASENRA AZ Medical Information Coding Resource COVID Resources Eosinophil Calculator Instructions for Use Patient Tools Prescribing Information Request a Rep Savings Program Stay Updated Video Library efficacy MOA safety dosing support resources diagnosis More Hide Power to Prevent Exacerbations Protection from OCS Study Designs References All Resources Access 360 How to Obtain FASENRA AZ Medical Information Coding Resource COVID Resources Eosinophil Calculator Instructions for Use Patient Tools Prescribing Information Request a Rep Savings Program Stay Updated Video Library NOW FDA APPROVEDFor Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)FASENRA is indicated as an add-on maintenance treatment of patients 12 years and older with severe eosinophilic asthma.FASENRA is not indicated for treatment of other eosinophilic conditions or for the relief of acute bronchospasm or status asthmaticus.#1 Prescribed Respiratory Biologic For Eosinophilic Asthma*1For uncontrolled eosinophilic asthma, choose a treatment option that isPOWERFUL, PRECISE, and PROVENFrom FIRST DOSE†2-5And NOW with data through 5 YEARS6See Study Designs.NOW FDA APPROVEDFor Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)QUICKLINKS01Access 36002Coding Resource 03Instructions for Use 04How to Obtain FASENRA 05Savings Program06Eosinophil Calculator *Based on IQVIA data from July 2020 to June 2021.1†In SIROCCO (48 weeks), a 51% reduction was observed in annual rate of asthma exacerbations in patients treated with FASENRA + SOC (n=267) vs placebo + SOC (n=267) (0.74 vs 1.52, P